Julio Licinio, MD, PhD, MBA, MS has made significant contributions to the fields of psychiatry and neuroscience, particularly through his extensive research and editorial leadership. Over his illustrious career, Dr. Licinio has been instrumental in advancing our understanding of complex psychiatric disorders, with a focus on depression, stress-related circuits, circadian rhythms, genetics, pharmacology, and pharmacogenomics. Dr. Licinio’s work has delved into the intricate mechanisms underpinning conditions such as obesity and depression, exploring their genetic and pharmacogenomic dimensions. This research has not only enriched the scientific literature but also paved the way for novel therapeutic strategies, contributing significantly to the field of precision medicine​. His exploration of the human microbiota and its impact on health further underscores his commitment to uncovering the multifaceted interactions between our environment, our biology, and psychiatric conditions​. As a testament to his prolific output, he has authored over 300 publications, which have had over 42,000 citations; his h-index is 90.  

In addition to his scientific accomplishments, Dr. Licinio has been recognized with prestigious honors, including his fellowship with the Australian Academy of Health and Medical Sciences, Matthew Flinders Distinguished Professor, and his role as State University of New York Distinguished Professor, highlighting his exceptional contributions to academia and medical research.​ One of Dr. Licinio’s notable contributions involves the implications of climate change on mental health, where he has explored the profound psychological impacts resulting from climate-induced stress and trauma. This work is particularly relevant in the context of increasing global environmental challenges, highlighting the intersection between psychiatry and broader societal issues​.

Dr. Licinio has over 30 years of experience as Editor-in-Chief, having founded and led four journals from inception to full indexing and high impact. In the last seven years, Dr. Licinio has edited and published 44 articles by 9 Nobel Prize laureates, including 19 by the late Nobel laureate Paul Greengard. Dr. Licinio rapidly raised the impact factor and rankings of the first journal he launched, which went from non-existent to number 1 worldwide in 13 years.

Our Editorial Board consists of eminent international experts. Confirmed members of the Editorial Board include:

Schahram Akbarian, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA

Daniel Barbosa, Medical University of South Carolina, Charleston, South Carolina 29425, USA

Tatiana Barichello, The University of Texas Health Science Center at Houston, Houston, Texas 77054, USA

Stefan R. Bornstein, TUD Dresden University of Technology, 01307 Dresden, Germany

Emiliana Borrelli, University of California, Irvine, California 92697, USA

Paolo Brambilla, Università degli Studi di Milano, 20122 Milan, MI, Italy

Joshua C. Brown, Harvard Medical School and McLean Hospital, Belmont, Massachusetts 02478, USA

Annamaria Cattaneo, Università degli Studi di Milano, 20133 Milan, MI, Italy

Udo Dannlowski, University of Münster, D-48149 Münster, Germany

Hamed Ekhtiari, University of Minnesota Medical School, Minneapolis, Minnesota 55454, USA

Massimo Filippi, Vita-Salute San Raffaele University, 20132 Milano, MI, Italy

Kostas N. Fountoulakis, School of Medicine, Aristotle University of Thessaloniki, Thessaloniki, Greece

Sam Gandy, Icahn School of Medicine at Mount Sinai, New York, New York 10029, USA

Ruben Gur, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA

Casey H. Halpern, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania 19104, USA

Alan G. Harris, New York University Grossman School of Medicine, New York, New York 10016, USA

Ian B. Hickie, University of Sydney, Brain and Mind Institute, Camperdown, New South Wales 2050, Australia

Atsushi Kamiya, Johns Hopkins School of Medicine, Baltimore, Maryland 21287, USA

Keith M. Kendrick, University of Electronic Science and Technology of China, Chengdu, China

Ronald C. Kessler, Harvard Medical School, Boston, Massachusetts 02115, USA

Beny Lafer, Universidade de São Paulo, 05403-903 São Paulo, São Paulo Brazil

Adrienne Carol Lahti, University of Alabama at Birmingham, Birmingham, Alabama 35294, USA

Tatia M. C. Lee, The State Key Laboratory of Brain and Cognitive Sciences, University of Hong Kong, Pokfulam, Hong Kong SAR

John Mantsch, Medical College of Wisconsin, Milwaukee, Wisconsin 53226, USA

Euripedes C. Miguel, Universidade de São Paulo, 05403-903 São Paulo, São Paulo Brazil

Valeria Mondelli, Institute of Psychiatry, Psychology and Neuroscience, King’s College, London, SE5 9RT, UK

Ruth O’Hara, Stanford University, Stanford, California 94305, USA

Anilkumar Pillai, University of Texas Health Science Center at Houston, Houston, Texas 77054, USA

Jelena Radulovic, Albert Einstein College of Medicine, Bronx, New York 10461, USA

Gavin Reynolds, Queen’s University Belfast and Sheffield Hallam University, UK

Marisa Roberto, The Scripps Research Institute, La Jolla, California 92037, USA

Isabelle M. Rosso, Harvard Medical School and McLean Hospital, Belmont, Massachusetts 02478, USA

Jonathan Savitz, Laureate Institute for Brain Research, Tulsa, Oklahoma 74136, USA

Akira Sawa, Johns Hopkins School of Medicine, Baltimore, Maryland 21287, USA

Helen Blair Simpson, Columbia University Vagelos College of Physicians and Surgeons, New York State Psychiatric Institute, New York, New York 10032, USA

Nuno Sousa, School of Medicine, University of Minho, 4710-057 Braga, Portugal

Weihong Song, Wenzhou Medical University, Wenzhou, 325015, China and University of British Columbia, Vancouver, British Columbia V6T 1Z3, Canada

Li-Huei Tsai, Picower Institute, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA

Kuei Y. Tseng, University of Illinois Chicago – College of Medicine, Chicago, Illinois 60612, USA

Lucina Uddin, University of California, Los Angeles, California 90095, USA

Guido van Wingen, University of Amsterdam, Amsterdam, 1100DD, The Netherlands

Roger Walz, Universidade Federal de Santa Catarina, Florianópolis, Santa Catarina 88040-970, Brazil

Yunlei Yang , Albert Einstein College of Medicine, Bronx, New York 10461, USA

Wei-Dong Yao, State University of New York, Upstate Medical University, Syracuse, New York 13210, USA

Keqiang Ye, Shenzhen Institute of Advanced Technology (SIAT), Chinese Academy of Sciences, Shenzhen, 518055, Guangdong, China

Allan H. Young, Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, SE5 8AF, UK

Tifei Yuan, Shanghai Mental Health Center, Brain Health Institute, 200030 Shanghai, China

Mone Zaidi, Icahn School of Medicine at Mount Sinai, New York, New York 10029-5674, USA

1. Journal Overview

Brain Medicine: From Neurons to Behavior and Better Health (Brain Medicine) is the first journal to comprehensively span all brain-related disciplines, uniting basic neuroscience with clinical practice and public health. We explore the origins, treatments, and societal implications of brain disorders, covering a spectrum from molecular genetics and neuroimaging to epidemiology and community health.

2. Aims & Scope

Brain Medicine aims to advance progress in fundamental neurobiology, translation, clinical medicine, and societal implications relevant to all brain disorders. The concept of "brain medicine" as a distinct entity has been advanced in the USA by Brown JC et al. (2023, PMID: 37021384) and Canada by Levitt S et al. (2023, PMID: 36719701) and Saravi SFB et al. (2023, PMID: 37227080), particularly for complex clinical presentations.

Why is this important? Currently, the brain and its disorders are covered by a myriad of separate disciplines that include, among others, neuroscience, neuroanatomy, neurophysiology, neuropathology, neuropsychopharmacology, microbiology, psychoneuroimmunology, psychoneuroendocrinology, psychiatry, neurology, neurosurgery, ophthalmology, otolaryngology, and rehabilitation medicine. We aim to provide one setting as the best venue to advance the emerging integrative discipline of brain medicine, breaking down historical, academic, institutional, and administrative barriers and showcasing the remarkable progress in research focused on the brain and its disorders.

Our scope, which stands as our hallmark, covers foundational neuroscience, reaches into translational efforts, and encompasses all conditions influenced by the brain. This includes neurological and psychiatric disorders, behavioral alterations as well as other aspects of health and illness that are controlled by the brain, such as obesity and body weight regulation, highlighting the brain's central role in these areas.

We publish work that utilizes various approaches, including genetics, cellular and molecular neuroscience, the "-omics," neuroimaging, neuropsychopharmacology, functional neurosurgery, brain stimulation, microbiology including the microbiome, psychoneuroimmunology, psychoneuroendocrinology, analyses of "big data," computational approaches including artificial intelligence (AI), environmental contributions, digital health, e-health, all the way to the societal impact of brain disorders, including epidemiology and public health.

Article Types

Brain Medicine accepts 28 different article types to accommodate the full spectrum of brain medicine research and scholarship. From traditional original research articles and comprehensive reviews to innovative formats like data reports, study protocols, and multimedia presentations, we provide authors with the flexibility to choose the format that best suits their work. Complete descriptions of all article types and their requirements are available in our Author Instructions.

3. Open Access Statement

Brain Medicine is a fully Open Access journal committed to the immediate, free dissemination of scientific knowledge.

We publish all content under the Creative Commons Attribution 4.0 International License (CC BY 4.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Articles published prior to 17 June 2025 were published under CC BY-NC-ND 4.0; however, all new submissions are published under the more permissive CC BY 4.0 license (https://creativecommons.org/licenses/by/4.0/deed.en). This means:

• Immediate free access: All articles are freely available to read, download, and share immediately upon publication
• No subscription barriers: No login requirements or paywalls restrict access to our content
• Reuse rights: Readers may copy, distribute, transmit, and adapt the work for any purpose, including commercial use, with proper attribution
• Author retention of copyright: Authors retain copyright of their work while granting the journal the right to publish
• Global accessibility: Our content is accessible worldwide without geographic or institutional barriers
• Machine readability: Full-text articles are available in formats suitable for text mining and computational analysis
• Permanent access: All published content remains freely accessible in perpetuity

This Open Access model ensures that research findings reach the widest possible audience, including researchers, clinicians, policymakers, patients, and the general public, thereby maximizing the impact and utility of published work.

Complete information about our Open Access policy is available at https://genomicpress.kglmeridian.com/view/journals/brainmed/brainmed-overview.xml/about

4. Mission and Values

Our mission is to be the primary venue supporting brain medicine's emergence as a new and cross-disciplinary discipline. Brain Medicine will expand knowledge from brain cells and circuits to brain disorders, covering their impact on society to achieve this mission. We are particularly interested in publishing work that is conceptually novel or that has potential for translational impact.

The core values of Brain Medicine include

• Excellence in all aspects of our publishing activities
• Academic integrity and scientific rigor throughout the review and publication process
• Passionate purpose to be instrumental in the emergence of brain medicine as a discipline
• Relentless innovation leading to translation from bench to bedside
• Inclusive and cross-disciplinary team science

We foster a culture of fairness and respect by assessing papers based solely on their merits and potential contributions to the field, regardless of origin.

5. Research Impact and Visibility

Brain Medicine publishes high-impact research that consistently receives exceptional attention from both the scientific community and global media. Our articles have been featured in major international news outlets across North America, Europe, Asia-Pacific, and beyond, demonstrating their relevance and importance to global public health and scientific advancement.

Multiple publications in Brain Medicine have achieved extraordinary global recognition:

Our groundbreaking study linking air pollution to autism risk, featured as the cover story in our inaugural issue, has been covered by more than 190 news media outlets across 10+ languages worldwide. The extensive coverage included premier publications in multiple languages:

• English: Fox News, Daily Mail, Newsmax, Manchester Evening News, and more than 130 regional news outlets across the United States and United Kingdom
• French: Pourquoi Docteur, Netcost-Security
• Italian: Sanitainformazione, Fanpage, and 9 other major outlets
• Spanish: InfoSalus and other outlets
• Greek: Multiple outlets including AMNA, IEfimerida, and Iatropedia
• Other languages: Coverage in Polish, Dutch, Serbian, and additional languages

Similarly, our microplastics research publication was covered by over 350 news outlets in 21 languages worldwide, including premier publications such as The Washington Post, Newsweek, Associated Press, National Post, Frankfurter Allgemeine, El País, and South China Morning Post.

This exceptional pattern of global media coverage across multiple publications firmly establishes Brain Medicine as an important international forum for disseminating critical developments in neuroscience and brain medicine. While our traditional academic citation metrics continue to develop as a newer journal, our content has already demonstrated substantial real-world impact through extensive media coverage and public health influence. This strong public engagement complements our commitment to publishing scientifically rigorous research from leading international researchers that addresses pressing questions in brain medicine.

6. Article-Level Metrics and Impact Tracking (Altmetric)

Brain Medicine provides comprehensive metrics for all published articles through our partnership with Altmetric, a leading provider of alternative metrics that track the online attention and engagement surrounding scholarly research.

Altmetric Integration

Every article published in Brain Medicine receives an Altmetric badge that visually represents the online attention it has received. These distinctive, colorful "donuts" appear on all article pages and provide:

• Real-time tracking of mentions across diverse sources including news media, social media platforms, policy documents, patents, and scholarly blogs
• Detailed breakdowns showing where and how research is being discussed, shared, and used beyond traditional citations
• Geographic reach displaying the global distribution of attention to published research
• Attention scores that help authors, institutions, and readers quickly assess the broader impact and public engagement with research

This integration complements traditional citation metrics by capturing the immediate societal impact and public engagement with research published in Brain Medicine, demonstrating how our articles contribute to public discourse, policy discussions, and knowledge dissemination beyond the academic community.

Authors can track their article's performance in real-time, and institutions can monitor the broader impact of their researchers' work, making Brain Medicine an attractive venue for researchers seeking maximum visibility and engagement for their findings.

7. Governing Body and Editorial Structure

Brain Medicine is led by an editorial board comprising over 45 internationally recognized experts in neuroscience, neurology, psychiatry, and related fields from prestigious institutions across North America, Europe, Asia, and Australia. Our editorial board members represent 12 different countries and more than 35 world-renowned research institutions, including Harvard Medical School, Icahn School of Medicine at Mount Sinai, Johns Hopkins, University of Pennsylvania, Stanford University, King's College London, University of Hong Kong, and the Chinese Academy of Sciences.

This diverse international representation ensures comprehensive expertise across the entire spectrum of brain medicine disciplines, from molecular neuroscience to clinical practice and public health. Our editorial team includes specialists across various brain-related disciplines, ensuring thorough oversight of the journal's scope and maintaining the highest quality standards for published content. This global network of leading researchers helps Brain Medicine attract high-quality submissions from around the world and provides expert peer review across all brain-related disciplines.

The complete list of Editorial Board members and their affiliations is available at https://genomicpress.kglmeridian.com/view/journals/brainmed/brainmed-overview.xml?journal-tabs-desktop=Editorial+Board

8. Peer Review Process

The foundation of scientific evaluation, peer review, is paramount in assessing research funding and scholarly outcomes. We uphold the integrity of the editorial process, grounded in unbiased peer review.

Brain Medicine employs single-blind peer review, the most commonly used approach globally. In this process, reviewers know the authors' identities, but authors do not know their reviewers' identities. This approach helps reviewers make informed assessments while protecting reviewer anonymity.

Every contribution to Brain Medicine, encompassing original research, reviews, letters, and all manuscript variants, undergoes comprehensive external peer review. The only exceptions are clearly marked informational editorials and interviews penned or edited as broad commentaries by the Editor-in-Chief.

Review Timeline

We are committed to providing timely peer review while maintaining rigorous standards. Authors can typically expect initial editorial decisions within 2-4 weeks of submission. This efficient review process ensures that important research reaches the scientific community promptly while maintaining the thoroughness necessary for high-quality peer review. The total average time from submission to publication is 43 days for Brain Medicine.

We are committed to maintaining the international character of Brain Medicine. Submissions are typically routed to eight scholars from different countries, ensuring a global distribution of reviewers. We strive to base editorial judgments on at least three critiques, though two may suffice in certain circumstances.

9. Publication Ethics and Scientific Integrity

At Brain Medicine, scientific integrity is our cornerstone. We uphold the highest standards of scientific excellence through complete transparency and uncompromising honesty. As part of our commitment to publication ethics:

Ethical Guidelines

• All papers undergo rigorous peer review (see above)
• All submissions are screened for plagiarism of text, figures, and images
• We maintain clear policies regarding conflicts of interest, requiring disclosure from all authors, reviewers, and editors
• We follow ethical guidelines for research involving human subjects and animals
• We adhere to best practices for authorship attribution and credit

Complete information about our plagiarism screening policy is available at https://genomicpress.kglmeridian.com/view/journals/brainmed/brainmed-overview.xml/about

Misconduct Investigation

We take potential misconduct seriously while recognizing the limitations of a journal's role in such matters. When concerns about potential misconduct arise, our approach is measured and procedural:

1. Initial inquiries are directed to the corresponding author, seeking clarification on questioned issues
2. If author explanations are insufficient or concerns persist, we may contact all co-authors to ensure awareness
3. For unresolved concerns, we notify the authors' institution(s) so that a formal institutional inquiry can be conducted, as journals cannot compel authors to provide original data or conduct formal investigations
4. We cooperate with institutional investigations while respecting their authority in addressing potential misconduct by their researchers

This balanced approach respects both the need for scientific integrity and the appropriate roles of journals versus research institutions in addressing misconduct concerns.

Publication Corrections

When correcting the published record, we take a contextual approach:

• Issuing errata for honest errors that do not impact overall conclusions
• Reserving retractions for cases involving misconduct, errors that undermine findings, extensive plagiarism, or overall loss of confidence in the work

While we largely align with the Committee on Publication Ethics (COPE) guidelines, we maintain flexibility to take different approaches when circumstances require. This may involve communicating with authors' institutions, funders, or other relevant oversight bodies to enable thorough investigations.

Appeals and Complaints Process

Authors who wish to appeal editorial decisions or lodge complaints about the peer review process should follow these procedures:

1. Initial Appeal: Submit a detailed appeal letter to the Editor-in-Chief via support@genomicpress.com within 30 days of the decision, explaining why the decision should be reconsidered
2. Review Process: Appeals are reviewed by the Editor-in-Chief, who may, at their discretion, consult with relevant Editorial Board members who were not involved in the original decision
3. Timeline: Authors can expect a response to appeals within 2-3 weeks
4. Final Decision: The Editor-in-Chief's decision on appeals is final
5. Complaints: For complaints about editorial processes, ethics, or other concerns, contact support@genomicpress.com. All complaints are investigated thoroughly and addressed within 21 days

Data Sharing and Reproducibility Policy

To promote transparency and reproducibility in research:

1. Data Availability Statement: All manuscripts must include a data availability statement describing where supporting data can be found
2. Encouraged Practices: Authors are strongly encouraged to:
   • Deposit raw data in appropriate public repositories (e.g., GEO, dbGaP, Dryad, Figshare)
   • Share analysis code and scripts via GitHub or similar platforms
   • Provide detailed methods to enable replication
3. Minimum Requirements: At minimum, authors must make available:
   • Data underlying all figures and tables
   • Custom code or algorithms essential to the conclusions
   • Detailed protocols for novel methods
4. Exceptions: Restrictions may apply for patient privacy, proprietary data, or ethical constraints, which must be clearly stated
5. Materials Sharing: Authors must agree to share unique materials (e.g., antibodies, cell lines, constructs) with qualified researchers upon reasonable request

Post-Publication Discussion Policy

We encourage scholarly discourse and maintain the integrity of the published record:

• Letters to the Editor: Readers may submit letters commenting on published articles within 6 months of publication
• Author Response: Original authors are invited to respond to substantive criticisms
• Post-Publication Review: We welcome post-publication peer review via established platforms (e.g., PubPeer)
• Social Media: Authors and readers are encouraged to discuss articles on social media using article DOIs

10. Publishing Schedule and Access

Print Edition

• ISSN: 2997-2647
• First Issue: January 2025
• Frequency: Every two months

Online Edition

• ISSN: 2997-2639
• Early Online Release: Began January 2024
• Open Access
• Publication Type: Postpub

Brain Medicine began with Early Online Release articles in January 2024, followed by our first formal print issue in January 2025. We have maintained our bi-monthly publication schedule with the January, March, and May 2025 issues already published and our July 2025 issue currently in production. Articles are made available online immediately upon final acceptance and production, with our content accessible through our dedicated website in an Open Access format.

11. Indexing Status and Publication Information

Brain Medicine is registered with Crossref, providing all publications with searchable DOI links. Our DOI prefix is 10.61373.

The journal is indexed with the US Library of Congress, Scilit, and Google Scholar, ensuring our published research receives broad visibility in academic searches.

The journal has been assigned NLM ID 9919032803506676 and is listed in the NLM catalog, demonstrating our commitment to meeting MEDLINE standards.

PubMed Central Compliance

Brain Medicine supports authors in meeting funder mandates for public access. While we are actively pursuing full MEDLINE/PubMed indexing, authors can currently deposit their accepted manuscripts in PubMed Central (PMC) to comply with NIH and other funding agency requirements. Successfully deposited manuscripts appear in PubMed with the designation "Author Manuscript" and receive PubMed IDs (PMIDs). For example, PMIDs 40510891 and 40401242 represent Brain Medicine articles currently accessible through this mechanism.

As a scholarly-driven publication, we are actively pursuing indexing in additional respected databases, including Medline/PubMed/Index Medicus, Scopus, Embase, and Clarivate (including Emerging Sources Citation Index, Journal Citation Reports and Web of Science). We are implementing an indexing strategy that will lead to inclusion in these platforms upon meeting their requirements, making prior submissions accessible retrospectively through those databases. We are taking all necessary measures to meet MEDLINE selection criteria and anticipate applying for full indexing in the near future.

12. Archiving and Long-term Preservation

Brain Medicine is committed to ensuring permanent access to all published research through our partnership with Portico, a leading digital preservation service. We have recently deposited all our published issues with Portico, guaranteeing that our content will remain accessible to the scholarly community for generations to come.

About Portico

Portico is a community-supported digital preservation service that has been safeguarding scholarly content since 2005. As part of ITHAKA---a nonprofit organization dedicated to expanding access to knowledge and education worldwide---Portico serves as a trusted guardian of digital scholarship for over 1,000 publishers and 1,000 libraries globally.

Key features of Portico preservation:

• Certified Trustworthy Repository: Portico has been certified by the Center for Research Libraries as a Trustworthy Digital Repository, confirming that its practices meet the highest standards set by the preservation community
• Dark Archive Protection: Portico operates as a "dark archive," meaning content is preserved securely and made accessible if specific trigger events occur, ensuring uninterrupted access to research
• Triple Redundancy: Content is preserved in three geographically distributed locations for maximum security and protection against any form of data loss
• Format Migration: Portico continuously monitors and migrates content to new formats as technology evolves, ensuring your research remains accessible regardless of future technological changes
• Perpetual Access: Our partnership with Portico guarantees that all Brain Medicine content will remain available to researchers, students, and scholars indefinitely, supporting the continuity of scientific knowledge

This comprehensive preservation strategy demonstrates our commitment to the long-term stewardship of the research we publish, ensuring that the important work appearing in Brain Medicine will continue to contribute to scientific progress for decades to come.

13. Copyright and Licensing Policies

Brain Medicine maintains clear copyright and licensing policies that are accessible to all authors and readers. All published articles clearly indicate the copyright holder. As an Open Access journal, we publish content under a Creative Commons license, with specific terms clearly stated on each published article in both HTML and PDF formats.

Our website provides detailed author guidelines that include complete information about our copyright policies, licensing terms, and any requirements regarding the posting of final accepted versions or published articles on third-party repositories. Complete information about our copyright and licensing policies is available at https://genomicpress.kglmeridian.com/view/journals/brainmed/brainmed-overview.xml/about

14. Author Fees and Revenue Sources

Brain Medicine operates on an Article Processing Charge (APC) business model, with all revenue generated through these publication fees. Our APC structure provides the financial foundation for our high-quality peer review, production, and publication processes while maintaining our Open Access status.

Complete information regarding our APC rates is clearly stated on our website in a location that is easily accessible to potential authors prior to manuscript submission. We maintain full transparency about our funding model to ensure authors understand the costs associated with publication. Information about publication fees is available at https://genomicpress.kglmeridian.com/view/journals/brainmed/brainmed-overview.xml/about

The academic and scholarly event announcements from non-profit organizations that appear in our journal are either provided at cost or offered free of charge as a service to the academic community. These announcements do not constitute a significant revenue source and are primarily included as a service to our readership.

15. Advertising Policy

Brain Medicine maintains a restricted advertising policy that only accepts announcements from non-profit organizations for academic and scholarly events. We do not accept any commercial advertising. This selective approach ensures that any advertisements appearing on our website or in our publications are directly relevant to our academic audience and aligned with our scholarly mission. All such non-profit academic announcements are clearly distinguished from editorial content and are not related in any way to editorial decision-making. Our advertising policy is publicly available on our website to ensure complete transparency.

16. Ownership and Management

Brain Medicine is published by Genomic Press, a specialized academic publisher focused on advancing open scientific communication in medicine and biosciences. Complete information about our ownership structure and management team is available on our website.

17. Contact Information

Editorial Office: Complete contact information for editorial inquiries is available on our website.

Author Guidelines: Detailed submission requirements, article type descriptions, and formatting instructions are available in our comprehensive Author Instructions.

Manuscript Submission: All manuscripts should be submitted through our online Submission Portal.

For general correspondence and additional information, please visit our website or contact our editorial office directly at support@genomicpress.com.

18. Direct Marketing Policy

Brain Medicine maintains ethical standards in all marketing and solicitation activities:

1. Targeted Communications: We only contact researchers whose work aligns with our journal's scope
2. Opt-out Mechanism: All marketing communications include clear unsubscribe options
3. No Spam: We do not engage in mass unsolicited emails or aggressive marketing tactics
4. Transparency: All communications clearly identify Genomic Press and the specific journal
5. Respect for Privacy: We do not share contact information with third parties
6. Professional Standards: All marketing materials accurately represent our journal's scope, standards, and processes
7. No Misleading Claims: We do not make exaggerated claims about impact factors, indexing, or publication timelines

Publishing your research in Brain Medicine offers the distinctive merits of swift, individualized review, global propagation of your findings, widespread accessibility through press coverage, equitable cost, and an attentive yet expansive concentration on pioneering research in myriad domains, emphasizing advancements across the broad scope of brain medicine.

Amplifying Your Research Impact

In today's digital landscape, scientific communication extends far beyond traditional academic channels. At Brain Medicine, we have developed a proven strategy that has generated over 500 news stories in more than 10 languages within our first two months of publication. Our comprehensive approach ensures your work achieves maximum visibility while maintaining rigorous scientific integrity.

Global Distribution Through EurekAlert!

All newsworthy articles published in Brain Medicine are distributed through EurekAlert!, the world's leading science news service operated by AAAS. EurekAlert! has specific eligibility guidelines that news releases must meet to be accepted and hosted on their platform. Rest assured that Genomic Press will cover all submission fees associated with your press release. However, please note that payment of these fees does not guarantee acceptance by EurekAlert!

Genomic Press’ recent success stories through EurekAlert! demonstrate the power of this approach:

• Multiple Sclerosis Research: 124 media outlets worldwide
• Depression Treatment Analysis: 88 media outlets across 10 languages
• Body Dysmorphic Disorder Study: 80+ global media outlets
• Liver X Receptor Research: Multiple languages including Lithuanian, French, Portuguese

Each newsworthy paper receives coverage through:

• EurekAlert! English language service (12,000+ journalists)
• Multiple language versions (Spanish, French, Chinese, Japanese, Arabic)
• Specialized scientific channels targeting specific research communities

Strategic Digital Dissemination

We leverage various social media platforms strategically:

• LinkedIn: Connect with industry leaders, potential collaborators, and research organizations
• X (formerly Twitter): Engage in real-time with the global scientific community
• Facebook: Reach broader academic audiences through established scientific groups
• Instagram: Transform complex concepts into visually engaging content
• YouTube: Share in-depth interviews and methodology explanations

Comprehensive Press Distribution

Beyond EurekAlert!, our press office maximizes impact through:

• International press release networks
• Specialized science media outlets
• Institutional press offices
• Scientific news services

The success of our approach is evident in the rapid global uptake of research published in Brain Medicine. At Genomic Press, our goal is not simply to publicize your research, but to foster meaningful engagement within both academic circles and the broader scientific community, as demonstrated by our achievement of over 500 media stories across multiple languages in our first two months.